JNJ-63709178 is a bispecific antibody that targets CD3, which is expressed on T-cells and CD123, which is overexpressed in various hematologic malignancies. JNJ-63709178 can redirect T-cells, resulting in T-cell mediated killing of CD123 positive acute myeloid leukemia (AML) cells. JNJ-63709178 was created under a collaboration between Genmab and Janssen Biotech, Inc. using Genmab's DuoBody® technology. 

Clinical studies
JNJ-63709178 is being investigated in acute myeloid leukemia.